Related Experiment Video

Updated: Jul 30, 2026

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

Insulin lispro lowers postprandial glucose in prepubertal children with diabetes

L C Deeb1, J H Holcombe, R Brunelle

  • 1Children's Clinic, Tallahassee, Florida 32308, USA. lcdeeb@attglobal.net

Pediatrics
|November 6, 2001
PubMed

Insights

Insulin lispro, a rapid-acting insulin analog, effectively lowers postprandial glucose in children with type 1 diabetes when given before meals. Post-meal administration showed comparable results to regular human insulin given pre-meal.

Area of Science:

  • Pediatric Endocrinology
  • Diabetes Management
  • Pharmacology

Background:

  • Type 1 diabetes in children requires careful glucose control.
  • Optimizing mealtime insulin regimens is crucial for managing postprandial hyperglycemia.
  • Insulin lispro offers a rapid-acting alternative to traditional insulins.

Purpose of the Study:

  • To compare the glucose-lowering efficacy of insulin lispro versus regular human insulin in prepubertal children with type 1 diabetes.
  • To evaluate the impact of insulin lispro timing (pre-meal vs. post-meal) on glycemic control.
  • To assess the safety profile of different insulin regimens.

Main Methods:

  • A 3-way crossover, open-label study involving 61 prepubertal children with type 1 diabetes.
  • Randomized assignment to regular human insulin (pre-meal) or insulin lispro (pre-meal or post-meal) combined with basal insulin.
  • Treatment periods of 3 months, with measurements of HbA1c and home glucose monitoring.

Main Results:

  • Insulin lispro given before breakfast and dinner significantly lowered 2-hour postprandial glucose compared to regular human insulin.
  • Post-meal insulin lispro resulted in glucose levels between pre-meal insulin lispro and pre-meal regular human insulin.
  • No significant differences were observed in HbA1c levels, adverse events, or hypoglycemia rates among the groups.

Conclusions:

  • Insulin lispro administered before meals is a safe and effective option for lowering postprandial glucose in prepubertal children.
  • Post-meal insulin lispro provides glycemic benefits comparable to pre-meal regular human insulin.
  • Timing of insulin lispro administration impacts postprandial glucose control in pediatric diabetes management.
Abstract

More Related Videos

Improving IV Insulin Administration in a Community Hospital12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Randomized Controlled Trial to Study the Acute Effects of Strength Exercise on Insulin Sensitivity in Obese Adults06:13

Randomized Controlled Trial to Study the Acute Effects of Strength Exercise on Insulin Sensitivity in Obese Adults

Published on: December 1, 2023

Related Concept Videos

Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...